LexaGene Engages LaVoieHealthScience as Integrated Investor and Public Relations Agency of Record
June 28 2021 - 7:45AM
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG), (the
“Company”), a molecular diagnostics company that develops fully
automated rapid pathogen detection systems, is pleased to announce
it has retained LaVoieHealthScience (LHS) as its investor and
public relations (IR and PR) agency of record.
LHS will work side-by-side with LexaGene’s senior management,
marketing, and financial teams to implement a comprehensive suite
of IR and PR services and counsel to help the Company gain
visibility among the investment community, as it charts a course
toward a potential up-listing to the Nasdaq Stock Market in the
United States.
LHS is a strategic, integrated communications firm with a keen
focus on helping life science and medical technology companies
solve complex communications challenges. The award-winning firm,
with roots in Boston’s life science hub, leverages its intimate
knowledge of the health care ecosystem and strong relationships
with the investment community and media to build recognition and
value for its clients. Founded in 2001 by Donna L. LaVoie,
President and CEO, a 30-year veteran in the health and science
industry, LHS fields a team of dedicated IR and PR specialists with
decades of experience gained from leading both health care
communications agencies and biopharmaceutical companies. LHS also
brings global capabilities and scale to its clients through its
strategic alliance with Omnicom Public Relations Group, Inc.
(OPRG), a division of Omnicom Group.
Dr. Jack Regan, LexaGene’s CEO and Founder, stated, “We’re
looking forward to working with LaVoieHealthScience. Their
specialization in serving life science and medical device companies
makes them the right firm to help bring LexaGene to the next level
of its corporate development. LHS’ deep understanding of the
markets we are targeting, both on the IR and PR side, will pay
dividends for LexaGene moving forward.”
The Company and LHS act at arm’s length and fees paid by the
Company to LHS are for its services only. Neither Ms. LaVoie or LHS
holds interest, directly or indirectly, in LexaGene Holdings, Inc.
or its securities, or any right or intent to acquire such an
interest. LexaGene will make monthly payments of USD$18,000 to LHS
for services rendered.
About LexaGene Holdings Inc.
LexaGene is a molecular diagnostics company that develops
molecular diagnostic systems for pathogen detection and genetic
testing for other molecular markers for on-site rapid testing in
veterinary diagnostics, food safety and for use in open-access
markets such as clinical research, agricultural testing, and
biodefense. End-users simply need to collect a sample, load it onto
the instrument with a sample preparation cartridge, enter sample ID
and press ‘go’. The MiQLab™ system delivers excellent sensitivity,
specificity, and breadth of detection and can return results in
approximately two hours. The unique open-access feature is designed
for custom testing so that end-users can load their own real-time
PCR assays onto the instrument to target any genetic target of
interest.
About LaVoieHealthScience
LaVoieHealthScience partners with leading health and science
brands to build value for their companies, attract capital, and
reach key stakeholders through integrated communications,
relationship building and marketing. The firm provides strategic
consulting, public relations, and investor relations to build
recognition and increase sales and value for health science
innovators. LHS also employs trademarked methodologies to enhance
its strategic communications advisory services. The agency has
received over 50 awards in recognition of the work done by its
strategic thinkers for leading clients in the healthcare and
science industries. LHS was inducted in the 2018 Inc. 5000 Hall of
Fame List of Fastest Growing Private Companies, as well as ranked
on the O’Dwyer’s list of 2021 Healthcare Public Relations Firms
and Boston Business Journal’s Largest PR Firms in
Massachusetts.
To learn more about LexaGene and the MiQLab System or subscribe
to company updates, visit www.lexagene.com, or follow us on Twitter
or LinkedIn.
On Behalf of the Board of DirectorsDr.
Jack ReganChief Executive Officer &
Chairman
The TSX Venture Exchange Inc. has in no way passed upon the
merits of the proposed transaction and has neither approved nor
disapproved the contents of this press release. Neither TSX Venture
Exchange nor its Regulation Services Provider (as that term is
defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking information, which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectation. Important factors — including the availability of
funds, the results of financing efforts, the success of technology
development efforts, the cost to procure critical parts,
performance of the instrument, market acceptance of the technology,
regulatory acceptance, and licensing issues — that could cause
actual results to differ materially from the Company’s expectations
as disclosed in the Company’s documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Contacts
Agency Contact: Media and Investors
Paul Sagan
VP, Investor Relations and Corporate Communications
617-374-8800
psagan@lavoiehealthscience.com
Katie Gallagher
Assistant Vice President, PR, and Media
617.792.3937
kgallagher@lavoiehealthscience.com
Corporate Contact:
Gail Winslow
Director of Corporate Marketing
gwinslow@lexagene.com
978.482.6237
ir@lexagene.com
800.215.1824
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jul 2023 to Jul 2024